Mealey's (February 6, 2019, 1:57 PM EST) -- WASHINGTON, D.C. — A final written decision by the Patent Trial and Appeal Board that invalidated various claims of a patented prostate cancer treatment was vacated and remanded Feb. 5 by...
Board Erred In Shifting Burden To Patent Owner, Federal Circuit Rules
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login